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Background: Hexose transporters (HT) are membrane proteins involved in the uptake of energy-supplying glucose
and other hexoses into the cell. Previous studies employing the Differential Display technique have shown that the
transcription level of the HT gene from T. cruzi (TcrHT) is higher in an in vitro-induced benznidazole (BZ)-resistant
population of the parasite (17 LER) than in its susceptible counterpart (17 WTS).
Methods: In the present study, TcrHT has been characterized in populations and strains of T. cruzi that are resistant
or susceptible to BZ. We investigated the copy number and chromosomal location of the gene, the levels of TcrHT
mRNA and of TcrHT activity, and the phylogenetic relationship between TcrHT and HTs from other organisms.
Results: In silico analyses revealed that 15 sequences of the TcrHT gene are present in the T. cruzi genome,
considering both CL Brener haplotypes. Southern blot analyses confirmed that the gene is present as a multicopy
tandem array and indicated a nucleotide sequence polymorphism associated to T. cruzi group I or II. Karyotype
analyses revealed that TcrHT is located in two chromosomal bands varying in size from 1.85 to 2.6 Mb depending
on the strain of T. cruzi. The sequence of amino acids in the HT from T. cruzi is closely related to the HT sequences
of Leishmania species according to phylogenetic analysis. Northern blot and quantitative real-time reverse
transcriptase polymerase chain reaction analyses revealed that TcrHT transcripts are 2.6-fold higher in the resistant
17 LER population than in the susceptible 17 WTS. Interestingly, the hexose transporter activity was 40% lower in
the 17 LER population than in all other T. cruzi samples analyzed. This phenotype was detected only in the
in vitro-induced BZ resistant population, but not in the in vivo-selected or naturally BZ resistant T. cruzi samples.
Sequencing analysis revealed that the amino acid sequences of the TcrHT from 17WTS and 17LER populations are
identical. This result suggests that the difference in glucose transport between 17WTS and 17LER populations is not
due to point mutations, but probably due to lower protein expression level.
Conclusion: The BZ resistant population 17 LER presents a decrease in glucose uptake in response to drug
pressure.
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The kinetoplastid protozoan Trypanosoma cruzi is the
causative agent of Chagas disease (American trypano-
somiasis), the pathogen, vector and clinical characteris-
tics of which were first described by Carlos Chagas in
1909. The disease currently affects 10–13 million people
in Latin America and is believed to have been respon-
sible for the deaths of more than 10,000 in 2008 [1].
The drugs nifurtimox (NFX; 5-nitrofuran-(3-methyl-4-
(5′- nitrofurfurylideneamine) tetrahydro-4 H-1, 4-tiazine-1,
1-dioxide); Bayer] and benznidazole [BZ; 2-nitroimidazole
(N-benzyl-2-nitroimidazole acetamide; Roche] are the
only medications presently available for the treatment of
Chagas disease, and both were developed empirically
some 40 years ago. There are a number of issues as-
sociated with the use of these drugs, including the low
percentage cure rate in the chronic phase (8%) compared
with that in the acute phase (76%) [2], the age-dependent
efficacy [3,4], and the undesirable side effects [5].
Another factor for concern is the appearance of parasite
populations that are naturally resistant to NFX or BZ,
and some with cross-resistance to both drugs [6-9]. The
problems associated with the available drugs, and the
lack of alternative medications, highlight the urgent need
to develop new strategies for chemotherapy against
Chagas disease [10].
One attractive approach to the identification of po-
tential therapeutic targets is to focus on genes that are
differentially expressed in strains of T. cruzi that are re-
sistant or susceptible to NFX or BZ. In order to pursue
this strategy, and with the additional objective of under-
standing the molecular basis of drug resistance, we have
previously investigated the levels of gene expression in
BZ resistant and susceptible T. cruzi populations using
Differential Display (DD) and Representation of Differ-
ential Expression (RDE) techniques [11]. The T. cruzi
hexose transporter gene (TcrHT) was one of four genes
indicated by DD as being over-expressed in an in vitro-
induced BZ resistant population (17 LER) of the proto-
zoan. This gene was first characterized by Tetaud et al.
[12], and comprises an open reading frame (ORF) of
1,635 bp encoding for 544 amino acids with a predicted
mass of 60 kDa. The TcrHT protein belongs to the Ma-
jor Facilitative Superfamily 1 (GLUT 1) of glucose trans-
porters [13,14], comprises 12 transmembrane domains
and is responsible for the cellular uptake of all energy-
supplying glucose and other hexoses. Once inside the
cell, the hexose is directed to a highly specific kineto-
plastid organelle, the glycosome, which contains the
enzymes involved in glucose and glycerol metabolism.
Various researchers have proposed hexose transporters
(HTs) as potential drug targets by virtue of their critical
role in glucose metabolism in the parasite or because
hexose deprivation could affect the virulence of theparasite [15-17]. In addition, TcrHT has the capacity to
transport D-fructose with a higher affinity than mamma-
lian HTs, thus increasing the chances of being able to
develop a more specific drug [18].
The aims of the present study were to characterize the
TcrHT gene in populations and strains of T. cruzi that
were either resistant or susceptible to BZ, and to estab-
lish the copy number and chromosomal location of the
gene, the levels of TcrHT mRNA and of TcrHT activity,
and the phylogenetic relationship between TcrHT and
HTs from other organisms.
Methods
Populations and strains of Trypanosoma cruzi
The provenances of the T. cruzi population with in vivo
selected BZ resistance (BZR) and its susceptible pair
(BZS), and of the pair of BZR and BZS clones (16R and
4 S, respectively), have been reported previously [19].
The BZ-resistant T. cruzi population (17 LER) derived
from the Tehuantepec cl2 susceptible wild-type strain
(17 WTS) [20] was obtained in vitro by increasing in a
stepwise manner the concentration of BZ. The 17 LER
parasites are resistant to a dose of BZ 23 times higher
than that required to kill 50% of the 17WTS parasites.
These parasites were kindly provided by Dr. Philippe
Nirdé (Génétique Moleculaire des Parasites et des
Vecteurs, Montpellier, France). The three naturally resist-
ant T. cruzi strains Colombiana, Yuyu and SC-28, and the
susceptible strain CL have been characterized previously
[6,7]. All of the populations and strains employed were
classified within T. cruzi groups I to VI according to the
nomenclature of Zingales et al. [21], and their epimasti-
gote forms were maintained in liquid liver infusion
tryptose (LIT) medium at 28°C [22].
In silico and phylogenetic analyses of the TcrHT gene
Similarity searches using the Basic Local Alignment
Search Tool (BLAST; National Center for Biotechnology
Information) (http://blast.ncbi.nlm.nih.gov/) were carried
out between the TcrHT sequence (GenBank accession
no.U05588), and the non-redundant database (nr–NCBI).
Based on this analysis, we were able to recover the PFAM
profile PF00083, which is an evolutionary model of “sugar
transporter protein”. Subsequently, using this PFAM
model, we used the hmmsearch tool [23] to search for
protein sequences related to the model in the predicted
proteomes of T. cruzi CL Brener Esmeraldo-like and non-
Esmeraldo-like [24] from TriTrypDB (http://tritrypdb.org/
common/downloads/release-4.1/Tcruzi/). The hmmsearch
returned the ID of those proteins related to PFAM
model. Each positive BLAST hit was analyzed and the re-
sult of the alignment was compared with information
available in the TriTrypDB database. In this study pro-
teins were used that had an E-value less than 1e-7.
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quence of TcrHT (GenBank accession no. U05588 or
TritrypDB Tc00.1047053506355-10) from T. cruzi CL
Brener non-Esmeraldo like predicted proteome was
compared against the proteomes of T. cruzi CL Brener
Esmeraldo like, two Trypanosoma spp. (T. congolense
and T. brucei), four species of Leishmania (L. brazi-
liensis, L. infantum, L. major and L. mexicana) and
Trichomonas vaginalis as outgroup. For each proteome
analyzed, the sequence with the highest similarity to
Tc00.1047053506355.10 was used in the phylogenetic
analysis. Initially, the sequences were aligned using the
MAFFT software [25]. It was used in local multiple
alignment mode which is suitable for analysis of a set
of proteins that possess isolated domains. The align-
ment generated was trimmed using TrimAl [26] to se-
lect blocks of conserved regions. This step guarantees
a better alignment quality. In order to choose the evo-
lutionary model which best fits with this alignment,
three models (JTT, Dayhoff and Blosum62) were tested
using the ProtTest version 2.4 [27]. The best model
according to ProtTest was JTT [28], and it was used
in the analysis. All other phylogenetic analysis steps were
performed using the PHYLIP package version 3.67 [29].
The first program used from the package was Seqboot
that generated 1000 alignments from the TrimAl align-
ment output. Subsequently, ProML was used along with
“analyze multiple dataset” option activated. This program
uses Maximum Likelihood as phylogenetic method.
Using the ProML program 1000 trees were generated.
To extract a consensus tree the program Consense also
from PHYLIP package was used. At the end of this
process, a phylogeny in NEXUS format was generated,
and it was read in FigTree version 1.2.3 software
(http://tree.bio.ed.ac.uk/software/figtree), which is a tree
figure drawing tool.
Extraction and preparation of RNA and DNA
The extraction and preparation of total RNA and gen-
omic DNA from T. cruzi populations, together with the
subsequent electrophoretic analyses, were carried out
according to previously described procedures [30]. For
the analyses of TcrHT genes, aliquots of genomic DNA
(14 μg) from each of the T. cruzi populations and strains
were digested with the restriction endonucleases SalI
and EcoRI (Invitrogen, Carlsbad, CA, USA). Southern and
Northern blots were hybridized with 32P labeled TcrHT
probes according to the protocol of Murta et al. [31].
Polymerase chain reaction (PCR)
In order to prepare the probes employed in Southern
and Northern blot assays, a 450 bp segment correspond-
ing to nucleotide 273 to 723 of the TcrHT (GenBank ac-
cession no. U05588) was amplified from T. cruzi Y strainDNA by PCR using the forward primer 5′ ATGCCATC-
CAAGAAGCAGACTGAT 3′ and the reverse primer 5′
CTGCCCGGCATAGATCGACCCAATC 3′. Amplifica-
tion was carried out in a Perkin Elmer (Waltham, MA,
USA) GeneAmp 9600 thermocycler with a reaction mix-
ture containing 0.5 Units of Taq DNA polymerase (Invi-
trogen), 1.5 mM MgCl2, 200 mM of each dNTP, 20 pmol
of each primer, 1 ng of T. cruzi DNA and 1X specific Taq
DNA polymerase buffer to a final volume of 10 μL. The
PCR program comprised an initial denaturation at 95°C
for 5 min, 30 cycles of denaturation at 95°C for 1 min,
annealing at 65°C for 1 min and extension at 72°C for
1 min, and a final extension at 72°C for 5 min. The PCR
product was subjected to electrophoresis on a 6% non-
denaturing polyacrylamide gel.
Real-time reverse transcriptase (RT)-PCR
The protocol used for the preparation of first strand
cDNA and the procedure for real-time RT-PCR were as
previously described [30]. An ABI Prism 7000 - Sequence
Detection System SDS (PE Applied Biosystems, Foster
City, CA, USA) was employed in the quantitative real-
time RT-PCR amplification of first strand cDNA using
the specific primers 5′ AGTTCCTTCACGTGGACG 3′
(forward) and 5′ CTGTGCCTTTTCTACGCT 3′(re-
verse) designed from the complete nucleotide sequence
of TcrHT (GenBank accession no. U05588). The T. cruzi
housekeeping gene hypoxanthine-guanine phosphoribo-
syltransferase (TcHGPRT), a T. cruzi single copy gene,
was employed to normalize the amount of each sample
assayed [31]. It is expressed at equivalent levels in all T.
cruzi samples analyzed presenting a Cq (Quantitation
cycle) of 22 ± 0.78. Standard curves were prepared for
each run using known quantities of pCR 2.1-TOPO
plasmids (Invitrogen) containing TcrHT and TcHGPRT
genes.
Pulsed-field gel electrophoresis (PFGE)
Chromosomes from different T. cruzi populations and
strains were separated by PFGE on an Amersham Phar-
macia (GE Life Sciences, Little Chalfont, UK) Gene
Navigator TM system as described previously [31]. Opti-
mized separations for TcrHT were obtained using PFGE
pulse intervals of: 250 s for 24 h, 500 s for 24 h, 750 s
for 24 h and 1000 s for 24 h at 90 V and 9°C. Following
electrophoresis, gels were stained with ethidium bromide
(0.5 μg/mL) and the chromosome bands were trans-
ferred onto nylon membranes and incubated with 32P-
labeled TcrHT probe in order to identify the gene.
Determination of TcrHT activity
The method of Eisenthal et al. [32] was used, with slight
modification, in order to assay the activity of TcrHT
in epimastigote forms of the populations and strains of
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sample of cells (2 x 105) was washed three times in
Krebs-Ringer phosphate (KRP) medium (pH 8.0) at room
temperature for 5 min at 2,000 x g, resuspended in KRP
to a final volume of 100 μL, and transferred to a separate
test tube. An aliquot (5 μL) of KRP containing 0.6 μCi of
6-deoxy-D-[6-3H] glucose (specific activity 11 Ci/mmol
or 66.7 mCi/mg) was added to each of the tubes and,
after a time interval of 30, 60 or 120 s, the T. cruzi HTs
were blocked by the addition of 200 μL of 2 mM phlori-
dizin (Sigma, Saint Louis, MO, USA). In order to obtain
an accurate estimate of TcrHT at 0 s, the cells represent-
ing this time interval were added to a tube after the glu-
cose and the phloridizin. Negative controls contained
cells and phloridizin, while positive controls contained
only radioactive glucose. After each time interval, the
tubes containing the reactions were centrifuged at 4°C
for 1 min at 10,000 x g, and the supernatants containing
glucose that had not been incorporated into the cells
were discarded. Parasites were lyzed after resuspending
in 500 μL of deionized water, and radioactivity was mea-
sured on a Beckman Coulter (Brea, CA, USA) model LS
liquid scintillation counter. The amount of glucose taken
up by a cell sample was estimated on the basis that 1 mol
of 6-deoxy-D-[6-3 H] glucose exhibited an activity of
9.26 e+15 cpm (determined by directly counting a known
amount of the radioactive substrate). For each population
or strain of T. cruzi, the total amount of protein present
in 2 x 105 cells was quantified using the standard Brad-
ford assay, and the amount of glucose transported per mg
of total protein was then calculated as a function of time.
Two-way analysis of variance (ANOVA) was used to com-
pare conjointly the uptake variables, namely, amount of
glucose and time. Data were analyzed using Minitab Stat-
istical Software (Minitab Inc., State College, PA, USA) at
the level of significance corresponding to α= 0.05.
DNA sequencing
The TcrHT 1,635 bp ORF from T. cruzi BZ-susceptible
and -resistant populations (17WTS, 17LER, BZS and
BZR) was cloned into the TOPO PCR2.1 vector (Invitro-
gen) and amplified in E. coli TOP 10 F’ competent cells.
Minipreparations of plasmid DNA were done using the
QIAprep Spin Miniprep kit (Qiagen). Aliquots of 500 ng
DNA were sequenced using the DYEnamicW ET Dye Ter-
minator Kit (GE Healthcare) in a MegaBACE 1000W DNA
Analysis System (GE Healthcare), using the following
primers: M13 forward 5′-GTAAAACGACGGCCAG-3′,
M13 reverse 5′-CAGGAAACAGCTATGAC-3′ and
internal TcrHT forward primers 5′-GCTCGTCCTAT
AACGGC-3′, 5′-CTGGAACTGACTGGCATC-3′, 5′-
TTGAGATTGGCCTTGGAC-3′ and reverse primers
5′-ATTGGGTAGCAGACGTTG-3′, 5′-AAAGTTCCAC
GCCATCAC-3′, 5′-AACGACACCTTGTGACCA-3′ and5′-GCATTCCCCATGTAT-3′. Reaction consisted of an
initial denaturation at 95°C followed by 30 cycles of 15 s
at 95°C, 20s at 55°C and 80s at 60°C. Samples were
analysed on Mega Bace 400 sequencer (Amersham) and
the data were analysed using Phred, Phrap and Consed.
Sequence variability between parasites was assessed by
sequencing three colonies of each T. cruzi population
and by sequencing each colony twice with each primer.
Sequences selected for analysis were those with Phred >
40. Nucleotide sequences were translated into the
amino acid sequence using Transec. The nucleotide and
amino acid sequences were aligned using the ClustalW
2.1 software.
Densitometric analyses
Southern and Northern autoradiograms were photo-
graphed and subsequently analyzed using ImageMaster
VDS software (GE Life Sciences, Little Chalfont, UK).
T. cruzi 24 S alpha small subunit was used as loading
control and for normalization of densitometric analysis
in Northern blot assays. Differences were considered sig-
nificant when the intensity band ratios were ≥ 2.0.
Results
In silico analyses of TcrHT gene
A similarity search of the TcrHT sequence showed that 15
sequences within T. cruzi CL Brener Esmeraldo-like
(TcChr-S - 7 sequences) and non-Esmeraldo-like (TcChr-
P – 8 sequences) matched the search criteria (Additional
file 1: Table S1). Among these sequences, nine sequences
were annotated as hexose/sugar transporter proteins,
being four complete copies (Tc00. 1047053508551.30,
Tc00.1047053511041.40, Tc00.1047053505183.130, Tc00.
1047053506355.10), three incomplete (Tc00. 1047053508551.
39, Tc00.1047053424937.10 and Tc00.1047053508231.9)
and two truncated (Tc00.1047053504125.100 and Tc00.
1047053506355.100). Seven of these copies were located
on chromosome TcChr37 of the Esmeraldo-like and non-
Esmeraldo like CL Brener haplotypes and two on the
chromosome TcChr26 of both haplotypes. Taking into
account, the four complete sequences, we observed that
three (Tc00.1047053508551.30, Tc00.1047053511041.40,
Tc00.1047053506355.10) were compatible to the previ-
ously described TcrHT (Tetaud et al., 1994) and were
aligned using ClustalW 2.1 software (Additional file 1:
Figure S1). Although the sequence Tc00. 1047053505183.
130 presents 12 transmembrane domains and it has been
annotated as a putative sugar transporter, it shows only
18% identity and 33% similarity when compared to the
reference sequence Tc00.1047053506355.10 (GenBank
accession no. U05588), thus it was not included our align-
ment analysis. The remaining six sequences were anno-
tated as hypothetical proteins, however, they present the
PFAM profile PF00083 and motif of “putative transporter
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TcChr39 of the Esmeraldo-like and non-Esmeraldo like
CL Brener haplotypes (Additional file 1: Table S1).
It is worth mentioning that the non-completion of
some of the sequences are due to their location in the
contig or to the size of the contig used in the genome
assemble. In the first case, the sequence started at the
end of the contig, which terminated before the gene se-
quence was completed. In the second case, the contig it-
self was smaller than the gene sequence. Based on these
findings as applied to version 2010-10-20 of the T. cruzi
genome, we can only speculate that this situation is a
function of the automatic annotation process adopted,
and/or the incomplete annotation of the genome, and/or
the highly repetitive content of the genome [33] consid-
ering that ca. 50% of the parasite genome consists of re-
petitive sequences [24].
In order to compare the amino acid sequence of
TcrHT with sequences of HTs identified in different try-
panosomatids, a maximum likelihood phylogenetic tree
was constructed (Figure 1). The HT of T. cruzi (Esmer-
aldo like and non-Esmeraldo like haplotypes) was more
closely related to the Leishmania species studiedFigure 1 Maximum likelihood phylogenetic tree based on sequences
organisms. In the consensus bootstrap tree (1000 replicates) shown, the n
percentage and the GenBank accession numbers are provided for each spe(namely, L. major, L. infantum, L. mexicana and L.
braziliensis) than to other species of Trypanosoma (i.e.
T. brucei and T. congolense). The very low identity (23%)
and similarity (37%) observed between the sugar
transporters of T. cruzi and Homo sapiens (GLUT 1)
reinforces the potential of TcrHT as a target for chemo-
therapy against Chagas disease.
Levels of TcrHT mRNA in T. cruzi populations
Hybridization of the Northern blots of total RNA from
T. cruzi samples against a specific [32P]dCTP labeled
TcrHT probe revealed one transcript of 2.6 kb for the
T. cruzi group I population with in vitro-induced re-
sistance (17 LER) and for its susceptible counterpart
(17 WTS). However, an additional transcript of 2.1 kb
was detected for the T. cruzi group II population with
in vivo-selected resistance (BZR) and for its susceptible
counterpart (BZS) (Figure 2A). In each case, a riboso-
mal RNA probe was used as a quantitative control
(Figure 2B). Comparison of the results of densitometric
analyses of transcript profiles of the populations (data
not shown) revealed that the levels of TcrHT mRNA were
2-fold greater in the drug-resistant 17 LER populationof hexose transporters of Trypanosoma cruzi and other
umbers above each branch represent the bootstrap confidence
cies included in the tree.
Figure 2 Levels of transcription of theTcrHT gene in BZ resistant and susceptible T. cruzi populations and strains showing: (A) Northern
blot profiles of total RNA extracts obtained using a 32P-labeled TcrHT-specific probe; (B) the quantitative control in which the same membrane
was exposed to a T. cruzi 24 S ribosomal RNA probe; and (C) levels of TcrHT mRNA as determined quantitatively (relative to the single-copy
housekeeping gene TcHGPRT) by real-time RT-PCR. Mean values of the copy number ratio TcrHT/TcHGPRT± standard deviations from three
independent experiments are indicated. The mean values for 17 WTS and 17 LER are significantly different (* p <0.001), whilst the BZR versus
BZS and the CL versus Colombiana mean values show no difference.
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no differences in mRNATcrHT levels for both transcripts
were detected between the BZR and BZS populations.
The results obtained from the quantitative real-time RT-
PCR analyses confirmed these findings and indicated
that the number of TcrHT cDNA molecules was 2.6-fold
higher in the 17 LER population than in the 17 WTS
population, while there were no differences in TcrHT
transcription levels between populations BZR and BZS
or between the naturally-resistant strain Colombiana
and the susceptible strain CL (Figure 2C).
Genomic organization and copy number of the TcrHT
gene
Southern blot assays were carried out using samples of
T. cruzi genomic DNA that had been restricted with the
endonucleases SalI, which has one restriction site within
TcrHT, and EcoRI, which has no restriction site withinFigure 3 Southern blot analyses of the TcrHT gene from BZ resistant
genomic DNA (14 μg) were digested with endonucleases SalI (A) or EcoRI
with a 32P-labeled TcrHT-specific probe. The molecular weight markers wer
digested with Hae III.the reference TcrHT sequence (U05588). Hybridization
of the blots of SalI-digested DNA against a TcrHT-
specific probe revealed a major band of 3.2 kb and an-
other less intense band of 2.8 Kb for all T. cruzi samples
analyzed (Figure 3A). In addition, the result showed two
bands of approximately 6.5 and 9.0 kb in populations 17
WTS and 17 LER from T. cruzi group I and two bands
of 8.0 and 9.5 kb in populations BZR, BZS and clones
4 S and 16R, from T. cruzi group II (Figure 3A). South-
ern blots of DNA that had been digested with EcoRI
showed one major band of 2.8 kb and three bands of ap-
proximately 4.0, 6.5 and 9.0 kb in populations 17 WTS
and 17 LER from T. cruzi group I, and two bands of 11.0
and 12.0 kb in populations BZR, BZS and clones 16R
and 4 S, from T. cruzi group II (Figure 3B). The band
profiles indicated that TcrHT is a multicopy gene, thus
confirming the findings of the in silico analyses. The
Southern blot assays also revealed that TcrHT exhibitsand susceptible T. cruzi populations and strains. Preparations of
(B), separated by electrophoresis on a 1% agarose gel and hybridized
e derived from λ phage DNA digested with HindIII and ϕX 174 DNA
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EcoRI restriction sites in the gene sequence present in
strains from T. cruzi group I that are absent in the gene
sequence present in strains from T. cruzi group II.
Densitometric analyses of the blots showed that the in-
tensities of the bands were similar in all of the T. cruzi
samples analyzed, signifying that TcrHT is not amplified
in the genome of T. cruzi resistant populations.
Chromosomal location of the TcrHT gene
The profiles obtained following PFGE separation of the
chromosomes of resistant and susceptible T. cruzi strains
are presented in Figure 4A. Southern blot analysis of
these chromosomes with a TcrHT-specific probe revealed
a marked heterogeneity in chromosome size (Figure 4B),
and showed that the gene is located on chromosomes
of ca. 1.85 and 2.02 Mb in T. cruzi group I (17 LER,
17 WTS and Yuyu) and of 2.21 and 2.6 Mb in T. cruzi
group II (BZR, BZS and clones 16R and 4 S). However,
the profile of SC-28, which is also classified as T. cruzi
group I, was clearly strain-specific with TcrHT located on
chromosomes of approximately 2.0 and 2.4 Mb. Com-
parison of the chromosomal bands recognized by the
TcrHT probe indicated that there were no differences be-
tween resistant and susceptible populations of T. cruzi.
This finding is consistent with the hypothesis that TcrHT
is not amplified in the genome of the resistant strains of
the parasite analyzed.
Activity of TcrHT in T. cruzi populations
Figure 5 displays the results of the HT activity assays
represented as the amount of glucose (mol) taken up by
the cells / total amount of protein (mg) at different time
intervals. With the exception of the resistant population
17 LER, the efficiencies of glucose transport were veryFigure 4 Chromosomal locations of theTcrHT gene in BZ resistant and
(A) chromosomal bands that had been separated by pulsed-field gel electr
obtained by hybridizing the chromosomal bands with a 32P-labeled TcrHT-s
were employed as molecular weight markers.similar for all T. cruzi samples analyzed at all time inter-
vals studied. Factorial ANOVA tests revealed that the
reduced rate of glucose transport observed for popula-
tion 17 LER in comparison with the other T. cruzi popu-
lations and strains was statistically significant (F = 90.12
and p < 0.001). Considering each resistant/susceptible
pair separately, the amount of glucose transported by
17 LER cells was, on average, 40% less than that trans-
ported by 17 WTS cells at all time intervals analyzed.
Factorial ANOVA tests showed that this difference was
also statistically significant (F = 1.148 and p < 0.001). No
differences in glucose transport were observed between
pairs BZR and BZS (p = 0.072) and between strains
Colombiana and CL (p = 0.5).Sequencing data
DNA sequencing of TcrHT gene from T. cruzi suscep-
tible and resistant strains was performed in order to in-
vestigate whether point mutations could be causing
difference in glucose uptake. Multi-alignment of the
TcrHT nucleotide and amino acid sequences revealed a
total of 31 nucleotide mutations (data not shown) lead-
ing to the substitution of 11 amino acid residues (Fig-
ure 6). We found no association between the nucleotide
mutations or amino acid substitutions and the resistance
phenotype. In contrast, we found that all 28 nucleotide
mutations and 9 of the amino acid substitutions were T.
cruzi strain-specific. Our analysis revealed that the nu-
cleotide and amino acid sequences of the TcrHT from
17WTS and 17LER were identical. This result suggests
that the difference in glucose transport between 17WTS
and 17LER populations is not due to point mutations,
but probably to differences in the TcrHT protein expres-
sion level.susceptible T. cruzi populations and strains showing:
ophoresis and stained with ethidium bromide; and (B) Southern blots
pecific probe. Whole chromosomes from Saccharomyces cerevisiae
Figure 6 Multiple sequence alignment of TcrHR amino acid sequences from four BZ-resistant or –susceptible T. cruzi strains. The figure
shows characteristics of the HT that are conserved in kinetoplastid: boxes indicate 12 transmembrane domains, asterisks indicate conserved
arginine residues and diamonds indicate cysteine residues. Amino acid residues in red colour and arrows indicate substitution.
Figure 5 Comparison of hexose transporter activities among BZ resistant and susceptible T. cruzi populations and strains showing the
quantities of 6-deoxy-D-[6-3 H] glucose transported per mg of total protein as a function of time. The values shown represent the means
of three independent experiments and the error bars indicate the standard error of the mean (± SEM). The mean values for 17 WTS and 17 LER
are significantly different (p <0.001), whilst the BZR versus BZS and the Colombiana versus CL mean values show no such differences
(p = 0.072 and p= 0.5, respectively).
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Hexose transporter proteins are considered to be poten-
tial targets for the development of therapies against
parasitic diseases since they could be inhibited, thus dis-
rupting the entry of vital nutrients into the parasite, or
employed as transporters of toxic compounds [15]. In
the present study, the gene encoding HT has been char-
acterized in populations and strains of T. cruzi that are
resistant or susceptible to BZ. The ORF of TcrHT is
1,635 bp in length and encodes for a protein of 544
amino acids with a predicted mass of 60 kDa. As is char-
acteristic of HTs belonging to the GLUT1 super family
of facilitative glucose transporters, the protein presented
12 conserved transmembrane domains. Phylogenetic
analyses showed that the amino acid sequence of TcrHT
is closely related (with identities of around 60%) to that
of other species of trypanosomatids. Much lower iden-
tities (< 25%) were observed between TcrHT and HT
sequences from mammals. One important prerequisite
in the selection of a potential target for chemotherapy
against a parasitic disease is that the target be absent, or
suitably distinct from its homologue, in the mammalian
host [34]. According to the data presented herein, it is
likely that a drug acting via TcrHT would be able to
affect the parasite without disrupting the metabolism of
the vertebrate host.
In silico and Southern blot analyses revealed that the
profile of TcrHT was consistent with a multicopy gene
and showed nucleotide sequence polymorphism related
to T. cruzi group. A total of 15 sequences related to
transporter protein were present in the T. cruzi database
[24]. Among these sequences, nine sequences were an-
notated as hexose/sugar transporter protein being four
complete copies, three incomplete and two truncated.
The remaining six sequences were annotated as hypo-
thetical proteins, however, they present the motif of
“putative transporter protein”. Tetaud et al. [12] had
previously determined by partial digestion of genomic
DNA that at least eight copies of TcrHT were present in
tandem array. More recently, Arner et al. [33] developed
an in silico approach involving multiple alignment of
any T. cruzi sequence against all sequences generated
by the genome project for this parasite and estimated
that the glucose transporter gene is present in 35 copies
in the diploid genome. The authors have chosen to treat
the two allelic copies of a gene as two gene copies. Then,
if we consider that each TcrHT gene is represented by
two allelic forms, there are approximately 17 copies of
this gene in the genome of the T. cruzi CL Brener. This
value is very close to that established in the present
study, and is supported by Southern blot analyses show-
ing that TcrHT exhibits a profile that is typical of a multi-
copy gene. The present study has revealed that TcrHT is
not amplified in the genome of any of the T. cruziresistant populations or strains investigated. Interest-
ingly, however, the TcrHT gene exhibits nucleotide poly-
morphism among the different strains analyzed, which is
associated with T. cruzi belonging to groups I or II.
Moreover, the TcrHT gene was found to be located in
two chromosomes in all of the resistant and susceptible
T. cruzi strains analyzed. In the T. cruzi chromosomal as-
semble [35], the TcrHT gene is also located in two chro-
mosomes, namely, the TcChr37-S and TcChr26-S from
the Esmeraldo-like haplotype, and the TcChr37-P and
TcChr26-P from the non-Esmeraldo like haplotype. The
remaining sequences annotated as hypothetical protein
(putative transporter protein) are located on chromo-
some TcChr13 and TcChr39 of both CL Brener haplo-
types. Clearly, chromosomal location of TcrHT is not
related to the drug resistance phenotype but is associated
with the T. cruzi group of the strain analyzed with the
single exception of strain SC-28, which presented a par-
ticular chromosomal pattern.
In the present study, Northern blot analyses of TcrHT
revealed one transcript of 2.6 kb for the population clas-
sified as T. cruzi group I and two transcripts of 2.1 and
2.6 kb for the populations classified as T. cruzi group II.
This finding is in accord with that of Tetaud et al. [12]
who detected transcripts of 2.1 and 2.6 kb in the T. cruzi
group II strain. According to these authors, the two
transcripts encode for the same protein and the size dif-
ference is due to variations in the 3' untranslated region.
It is known that specific sequences in this untranslated
region are capable of regulating gene expression [36,37],
since they permit the interaction with factors that stimu-
late or inhibit the transcription process according to the
developmental stage of the parasite.
Northern blot and real time-PCR analyses revealed
that the expression of TcrHT was 2.6-fold greater in the
resistant population 17 LER than in its susceptible coun-
terpart 17 WTS. Different attempts to produce poly-
clonal antibody against the TcrHT recombinant protein
failed, then unfortunately the protein expression level
could not be analyzed in these T. cruzi samples. As de-
scribed in the literature the hexose transporter activity
is an important approach to verify the involvement of
this transporter in the drug resistance phenotype. Then,
we analyzed the amount of glucose taken up by the cells
/ total amount of protein at different time intervals and
verified that the hexose transporter activity was 40%
lower in the 17 LER population than in all other T. cruzi
samples analyzed. These results could reflect a decrease
of TcrHT protein expression level in the BZ-resistant
population 17LER or these parasites could be expressing
a TcrHT isoform with lower affinity for glucose. Sub-
sequently, we analysed polymorphisms in the TcrHT nu-
cleotide and amino acid sequences. Our analysis revealed
that the TcrHT sequences from 17WTS and 17LER are
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cose transport between 17WTS and 17LER populations
is not due to point mutations, but probably to differences
in the TcrHT protein expression level. Since the regula-
tion of trypanosomatid gene expression occurs mainly at
the post-transcriptional level [38], maybe the mRNA of
the TcrHT gene in the resistant parasites may not be effi-
ciently translated, thus presenting lower protein expres-
sion that could reflect in the lower hexose activity. The
discrepancy between increased HT mRNA level and de-
creased glucose transport can not only be explained by
decreased protein expression but also by decreased trans-
port of the protein to the plasma membrane or increased
endocytosis of the transporter.
The regulation of the stability and translation of
mRNA plays a major role in modulating gene expression
in T. cruzi [39]. In addition to mRNA stability, some ele-
ments, consisting of AU-rich sequences improve trans-
lational efficiency by interaction with specific RNA
binding proteins (RBP) [40,41]. In agreement with our
results, an inverse correlation between mRNA and pro-
tein levels of some genes in T. cruzi has also been previ-
ously reported in the literature. Silva et al. [42] showed
that α and β tubulin mRNAs are three to six-fold more
abundant in epimastigote forms than in trypomastigote
and amastigote forms of T. cruzi. However, the protein
levels of free α and β tubulin subunits are more abundant
in trypomastigotes and amastigotes than in epimasti-
gotes. Metacyclogenin gene (TcMet) also suffers post-
transcriptional regulation, since a similar pattern of
TcMet mRNA expression is observed in both replicating
and differentiating epimastigote forms of T. cruzi. How-
ever, the TcMet protein was detected only in differen-
tiating epimastigotes [43]. Previous data obtained by our
group, also describes differences between mRNA and
protein levels of some T. cruzi genes. Although the levels
of TcTAT (tyrosine aminotransferase) and TcHSP-70
(heat shock protein 70 kDa) mRNAs were higher in the
T. cruzi BZ-resistant population 17LER, no correspond-
ing increases were observed in the levels of TcTAT and
TcHSP-70 protein expression [11,44].
It is known that the over-expression of members of
the ATP-binding cassette (ABC) superfamily of mem-
brane transporters can confer multidrug resistance in a
variety of organisms. However, Nourani et al. [45] have
shown that an ABC transporter knockout mutant of Sac-
charomyces cerevisiae maintained the multidrug resist-
ance phenotype and also presented decreased expression
of the hexose transporters HTX9 and HTX11. This find-
ing led to the suggestion that these transporters might
afford a route for drug entrance and that their down-
regulation would favor the survival of the yeast in the
presence of the drug. In support of this hypothesis,
Uzcategui et al. [46] reported a decrease of 80% inglucose transport in a strain of L. amazonensis resistant
to glibenclamide (GLIB), an inhibitor of ABC transpor-
ters, while Machuca et al. [47] showed that glucose ac-
cumulation in a GLIB-resistant strain of this parasite
was 4.5-fold slower than that of the susceptible parental
strain. Decreased glucose accumulation has also been
observed in GLIB-resistant cell lines of L. major [47].
The results of the present study suggest that the BZ re-
sistant population 17 LER presents a decreasing glucose
uptake in response to drug pressure, and that this could
favor the survival of the parasite in the presence of BZ
since less toxic compounds would enter into the cell.
Many of studies concerning drug resistance mechan-
isms in parasites were based on models produced by
artificial induction of resistance. In contrast, there is very
little information available on the biochemical mechan-
isms underlying drug resistance in field isolates. The
data presented in this paper show that the hexose trans-
porter TcrHT has a decreased degree of activity in the
in vitro induced BZ resistant T. cruzi population, a situ-
ation that is different from that observed in the in vivo
selected resistant line. In agreement with our results,
Villareal et al. [48] observed that the mechanisms asso-
ciated with natural resistance to drugs differ from those
in induced resistance. The mechanism of drug resist-
ance, such as that to BZ, is often complex and typically
ensues as a result of the concomitant activation of mul-
tiple, often overlapping, signalling pathways, including
factors associated with the host immune system, which
may enhance the susceptibility of the parasite to the
drug [49].Conclusion
As part of an on-going project dedicated to the elucida-
tion of the molecular basis of drug resistance in T. cruzi,
we have studied a selection of genes that are differ-
entially expressed in BZ resistant and susceptible pop-
ulations of the parasite [30,31,50]. The results obtained
suggest that the mechanisms by which resistant strains
of T. cruzi evade the effects of the drug are somewhat
complex, and highlight the necessity to perform func-
tional analyses of TcrHT in order to confirm our hy-
pothesis that TcrHT is involved in the drug resistance
phenotype. However, TcrHT can still be considered as a
potential therapeutic target since it constitutes the point
of uptake of essential nutrients for the parasite. A de-
crease in the influx of hexoses can compromise parasite
infection, since these sugars are essential for ATP pro-
duction and for the biosynthesis of glycoconjugates
that are secreted or expressed on trypanosomatid mem-
branes [51] and are directly related to virulence and the
ability of the parasite to escape from the immune system
of the host.
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Additional file 1 Table S1: Analysis of the TcrHT gene in the
genomic assembly of Trypanosoma cruzi. Figure S1. Multiple
sequence alignment of TcrHT amino acid complete sequences annotated
in the T. cruzi genome assembles. The figure shows characteristics of the
HT that are conserved in kinetoplastid: boxes indicate 12 transmembrane
domains, asterisks indicate conserved arginine residues and diamonds
indicate cysteine residues. Amino acid residues in colored indicate
substitution.
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